(Q30233733)

11 June 2017

1 reference

title

Some important issues in the planning of phase III HIV vaccine efficacy trials (English)

1 reference

11 June 2017

main subject

phase III clinical trial

0 references

author name string

Boily MC

1

1 reference

11 June 2017

Mâsse BR

2

1 reference

11 June 2017

Desai K

3

1 reference

11 June 2017

Alary M

4

1 reference

11 June 2017

Anderson RM

5

1 reference

11 June 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

11 June 2017

1 reference

11 June 2017

volume

17

1 reference

11 June 2017

issue

7-8

1 reference

11 June 2017

page(s)

989-1004

1 reference

HIV: to vaccinate or not to vaccinate?

11 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

International vaccine efficacy trials: special considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Efficacy trials for HIV/AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Immunization with Tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The ability of certain SIV vaccines to provoke reactions against normal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Statistical Issues in the Design of HIV Vaccine Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

HIV preventive vaccine research: selected ethical issues.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The highest attainable standard: ethical issues in AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Development of a vaccine for the prevention of AIDS, a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The needs and hopes for an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

A mathematical model of vaccination against HIV to prevent the development of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

HIV vaccines: where we are and where we are going

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Anti-HIV env immunities elicited by nucleic acid vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Update on the issues of HIV vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Planned tests in Thailand spark debate

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Clearance of HIV infection in a perinatally infected infant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Two candidates for a live AIDS vaccine emerge

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Drug delivery issues in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Experience from HIV incidence cohorts in Thailand: implications for HIV vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Review: collected materials and records of HIV/AIDS prevalence and the contemporary social changes in Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The role of behavioral research in HIV/AIDS prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Looking for leads in HIV's battle with immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Some statistical issues in HIV vaccine trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The behaviour of common measures of association used to assess a vaccination programme under complex disease transmission patterns--a computer simulation study of malaria vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The impact of heterogeneity in individual frailty on the dynamics of mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Study designs for dependent happenings

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Immunisation and herd immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

On Measures and Models for the Effectiveness of Vaccines and Vaccination Programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Sexual Contact Patterns between Men and Women and the Spread of HIV-1 in Urban Centres in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Assessing risk factors for transmission of infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Low-efficacy HIV vaccines: potential for community-based intervention programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Quantitative investigations of different vaccination policies for the control of congenital rubella syndrome (CRS) in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Imperfect vaccines and herd immunity to HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Assessment of the Protective Efficacy of Vaccines against Common Diseases Using Case-Control and Cohort Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Interpretation and estimation of vaccine efficacy under heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Estimation of vaccine efficacy in outbreaks of acute infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Measures of the effects of vaccination in a randomly mixing population

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

On individual and population effectiveness of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Estimability and Interpretation of Vaccine Efficacy Using Frailty Mixing Models

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Analyzing effects of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Simulation studies of phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Thailand weighs AIDS vaccine tests.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Introduction to sample size determination and power analysis for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Assessing HIV vaccine effects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Tables of the number of patients required in clinical trials using the logrank test.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Probability of female-to-male transmission of HIV-1 in Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Human immunodeficiency virus transmission and the role of other sexually transmitted diseases. Measures of association and study design.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Designing clinical trials with arbitrary specification of survival functions and for the log rank or generalized Wilcoxon test.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

A computer program for designing clinical trials with arbitrary survival curves and group sequential testing

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Sample size determination in clinical trials with time-dependent rates of losses and noncompliance

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

On the distribution of vaccine protection under heterogeneous response.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Jitters jeopardize AIDS vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

Why do we not have an HIV vaccine and how can we make one? .

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

The WHO and why of HIV vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900316-8

7 January 2021

10.1016/S0264-410X(98)00316-8

Identifiers

DOI

1 reference

11 June 2017

1 reference